Malta - Engels - Malta Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 20 mg - antineoplastic agents

Malta - Engels - Malta Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 30 mg - antineoplastic agents

Malta - Engels - Malta Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 80 mg - antineoplastic agents

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - fludioxonil - suspension concentrate - fludioxonil phenylpyrrole active 125.0 g/l - fungicide

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 200 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 500 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 1000 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 50 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Israël - Engels - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 100 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).